ALKS - Alkermes plc.

QQQ $ 629.16 $ 3.02 (0.48 %)

DIA $ 475.58 $ 0.66 (0.14 %)

SPY $ 681.80 $ 2.23 (0.33 %)

TLT $ 90.21 $ -0.27 (-0.3 %)

GLD $ 368.20 $ -2.01 (-0.54 %)

Previous Close

$ 30.7

Open

$ 30.70

Bid

$ 30.00 x 5

Ask

$ 32.45 x 200

Day's Range

$ 30.35 - $ 31.00

52 Week Range

$ 25.17 - $ 36.45

Volume

2,020,726

Average Volume

Market Cap

5.07B

Beta (5Y Monthly)

$ 0.47

PE Ratio (TTM)

$ 15.03

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	10-28-2025	09-30-2025	10-Q
2	07-29-2025	06-30-2025	10-Q
3	05-01-2025	03-31-2025	10-Q
4	02-12-2025	12-31-2024	10-K
5	10-24-2024	09-30-2024	10-Q
6	07-24-2024	06-30-2024	10-Q
7	05-01-2024	03-31-2024	10-Q
8	02-21-2024	12-31-2023	10-K
9	10-25-2023	09-30-2023	10-Q
10	07-26-2023	06-30-2023	10-Q
11	04-26-2023	03-31-2023	10-Q
12	02-16-2023	12-31-2022	10-K
13	11-02-2022	09-30-2022	10-Q
14	07-27-2022	06-30-2022	10-Q
15	04-27-2022	03-31-2022	10-Q
16	02-16-2022	12-31-2021	10-K
17	10-27-2021	09-30-2021	10-Q
18	07-28-2021	06-30-2021	10-Q
19	04-28-2021	03-31-2021	10-Q
20	02-11-2021	12-31-2020	10-K
21	10-29-2020	09-30-2020	10-Q
22	07-29-2020	06-30-2020	10-Q
23	04-29-2020	03-31-2020	10-Q
24	02-13-2020	12-31-2019	10-K
25	10-23-2019	09-30-2019	10-Q
26	07-25-2019	06-30-2019	10-Q
27	04-25-2019	03-31-2019	10-Q
28	02-15-2019	12-31-2018	10-K
29	10-23-2018	09-30-2018	10-Q
30	07-26-2018	06-30-2018	10-Q
31	04-26-2018	03-31-2018	10-Q
32	02-16-2018	12-31-2017	10-K
33	10-26-2017	09-30-2017	10-Q
34	07-27-2017	06-30-2017	10-Q
35	04-27-2017	03-31-2017	10-Q
36	02-17-2017	12-31-2016	10-K
37	11-02-2016	09-30-2016	10-Q
38	07-28-2016	06-30-2016	10-Q
39	04-28-2016	03-31-2016	10-Q
40	02-25-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Wells Fargo Maintains Overweight on Alkerm...
10/29/2025 14:16:48

Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and lowers the price target from $44...

Needham Maintains Buy on Alkermes, Raises ...
10/29/2025 09:55:29

Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target from $43 to $44.

Earnings Scheduled For October 28, 2025
10/28/2025 11:11:34

Alkermes Raises FY2025 GAAP EPS Guidance f...
10/28/2025 11:07:42

Alkermes (NASDAQ:ALKS) raises FY2025 GAAP EPS guidance from $1.03-$1.21 to $1.36-$1.47 vs $1.29 analyst estimate. Raises FY2025...

Alkermes Q3 EPS $0.49 Beats $0.30 Estimate...
10/28/2025 11:02:01

Alkermes (NASDAQ:ALKS) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.30 by 65....

Preview: Alkermes's Earnings
10/27/2025 20:01:37

deal-dispatch-from-four-roses-bourbon-to-quantum-stakes-here-are-this-weeks-sector-shake-ups

Deal Dispatch: From Four Roses Bourbon To ...
10/24/2025 16:20:19

Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across va...

Breaking Down Alkermes: 8 Analysts Share T...
10/23/2025 21:01:49

Piper Sandler Reiterates Overweight on Alk...
10/23/2025 16:26:16

Piper Sandler analyst David Amsellem reiterates Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from $3...

RBC Capital Maintains Outperform on Alkerm...
10/23/2025 13:22:37

RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $45 ...

alkermes-strikes-21-billion-avadel-deal-gains-access-to-narcolepsy-drug-lumryz

Alkermes Strikes $2.1 Billion Avadel Deal,...
10/22/2025 19:18:55

Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicin...

Alkermes To Acquire Avadel Pharmaceuticals...
10/22/2025 11:14:36

9 Analysts Assess Alkermes: What You Need ...
09/26/2025 13:00:29

Analysts' ratings for Alkermes (NASDAQ: ALKS) over the last quarter vary from bullish to bearish, as provided by 9 analysts...

this-ciena-analyst-turns-bullish-here-are-top-5-upgrades-for-friday

This Ciena Analyst Turns Bullish; Here Are...
09/26/2025 11:55:03

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

RBC Capital Upgrades Alkermes to Outperfor...
09/26/2025 11:40:04

RBC Capital analyst Leonid Timashev upgrades Alkermes (NASDAQ: ALKS) from Sector Perform to Outperform and raises the price ...

Alkermes Appoints Joshua Reed As CFO, Effe...
09/12/2025 13:01:24

JP Morgan Maintains Neutral on Alkermes, R...
09/09/2025 19:43:27

JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target from $34 to $35.

HC Wainwright & Co. Reiterates Neutral on ...
09/09/2025 10:48:19

HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $46 price target.

Alkermes Vibrance 1 Study Demonstrates Ali...
09/08/2025 07:18:30

– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cog...

Deep Dive Into Alkermes Stock: Analyst Per...
09/03/2025 20:00:35